98%
921
2 minutes
20
Objective: Preterm birth (PTB) remains a leading cause of neonatal morbidity and mortality across Europe despite advances in obstetric care. While PTB rates vary widely across the region, overall declines in recent decades have been limited, revealing persistent gaps in risk assessment and prevention.
Methods: Here we review current challenges and disparities in European PTB prediction and prevention, highlighting the complex constellation of maternal, fetal, environmental, and sociodemographic risk factors.
Results: Extending gestational age represents an opportunity to improve outcomes among pregnancies at higher PTB risk. Unfortunately, existing tools for PTB risk assessment and prevention show limited effectiveness arising from the fact that the PTB event is a frequent outcome with various underlying causes.The limitations of existing clinical prediction tools, which can only account for a minority of PTBs, underscore the need for more accurate and accessible screening methods. Although cervical length screening and some biomarkers demonstrate promise for risk stratification, they are not uniformly implemented, and the few effective interventions that risk stratification would implement lack broad consensus or standardization. These interventions, including progesterone therapy, low-dose aspirin, and lifestyle modifications, may require regional approaches reflecting population-specific risk profiles.
Conclusions: The PTB burden is a persistent concern across Europe. Constituent populations are diverse, comprising a mosaic of risk factors of varying significance that fail to predict the majority of PTBs. During this time of evolving demographics in the Europe, assessing PTB risk becomes even more challenging. The stagnation of PTB incidence rates also strongly suggests that new tools are needed to achieve improvements for mothers, babies, public health, and to reduce associated long-term costs of PTB. To move forward, optimizing gestational age and neonatal outcomes in Europe will require more unified guidelines, optimized implementation of known preventative strategies, investment in novel risk assessment tools, and public health policies that address modifiable risk factors both pre- and post-conception. Addressing these gaps is essential to reduce PTB-related health burdens and promote maternal and neonatal well-being across diverse European settings.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1080/14767058.2025.2547687 | DOI Listing |
Circ Cardiovasc Interv
September 2025
Keele Cardiovascular Research Group, Keele University, United Kingdom (M.A.M., R.B.).
Background: Evidence informing clinical guidelines assumes that all transcatheter aortic valve implantation (TAVI) devices have similar effectiveness, in other words, displaying a class effect across TAVI valves. We aimed to assess the comparative effectiveness of different TAVI platforms relative to other TAVI counterparts or surgical aortic valve replacement (SAVR).
Methods: MEDLINE/Embase/CENTRAL were searched from inception until April 2025, for randomized controlled trials comparing outcomes with different commercially available TAVI devices relative to other TAVI counterparts or SAVR.
Crit Rev Toxicol
September 2025
Centre for Health Protection, National Institute for Public Health and the Environment (RIVM), Bilthoven, Netherlands.
There is a concern on the safety of cosmetic ingredients and their endocrine-disrupting (ED) potential. Frequent use as well as the use of a diverse range of cosmetics pose a concern for a potential health risk via aggregate exposure to endocrine disrupting chemicals (EDCs). In this study, a list of ingredients available in cosmetic products that were recently introduced to the Dutch market was retrieved from the commercially accessible Mintel database and screened for the presence of EDCs.
View Article and Find Full Text PDFRev Med Liege
September 2025
Service de Chimie clinique, CHU Liège, Belgique.
Chronic kidney disease (CKD), heart failure (HF) and atherosclerotic cardiovascular disease (ASCVD) are pathologies that may remain silent for a long time and thus are largely underdiagnosed in clinical practice. The use of biomarkers may help detect people already suffering from these diseases at an early stage or at increased risk to develop them in a near future. The aim of this article is to discuss the place of the assays of albuminuria, natriuretic peptide (BNP/proBNP) and high-sensitivity troponin as well as lipoprotein(a) to help in the diagnosis and prognosis assessment of individuals at risk of presenting or developing a CKD, HF or ASCVD.
View Article and Find Full Text PDFJ Dance Med Sci
September 2025
Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil.
The aim of this study was to propose reference values for the Dynamic Evaluation Method of Lower Limb Joint Alignment (MADAAMI II). During the 2023 Joinville Dance Festival, 346 dancers (315 females and 31 males), aged between 15 and 58 years, with a minimum of 5 years of ballet experience, were randomly evaluated. The dancers were filmed performing the three-step sequence (demi plié, grand plié, and fondu) of the MADAAMI II, in the first foot position, with self-selected turnout and at 120 degrees.
View Article and Find Full Text PDFKnee Surg Relat Res
September 2025
Florida Orthopaedic Institute, Gainesville, FL, 32607, USA.
Background: A clear understanding of minimal clinically important difference (MCID) and substantial clinical benefit (SCB) is essential for effectively implementing patient-reported outcome measurements (PROMs) as a performance measure for total knee arthroplasty (TKA). Since not achieving MCID and SCB may reflect suboptimal surgical benefit, the primary aim of this study was to use machine learning to predict patients who may not achieve the threshold-based outcomes (i.e.
View Article and Find Full Text PDF